HAIFA, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer shares of its common stock and warrants to purchase shares of its common stock in a registered public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Jefferies & Company, Inc. is acting as sole book-running manager for the proposed offering. Oppenheimer & Co. Inc. is acting as co-lead manager for the proposed offering. Needham & Company, LLC and Maxim Group LLC are acting as co-managers for the proposed offering. In addition, Leader Capital Markets Ltd. is acting as the company’s financial advisor in connection with the proposed offering.
